The FDA cleared a remote electrical neuromodulation device (Nerivio, Theranica) for acute treatment of migraine in children as young as 12 years of age. Patients can be diagnosed with either episodic or chronic migraine.
FEBRUARY 1, 2021
FEBRUARY 1, 2021
The FDA cleared a remote electrical neuromodulation device (Nerivio, Theranica) for acute treatment of migraine in children as young as 12 years of age. Patients can be diagnosed with either episodic or chronic migraine.